News › ZEISS · FDA appr­oval for the CT LUCIA 621P mono­fo­cal IOL

With the mono­fo­cal IOL, sur­ge­ons can treat many cata­ract pati­ents and achieve opti­mi­zed visual outcomes.

ZEISS Medi­cal Tech­no­logy today announ­ced the appr­oval of the CT LUCIA® 621P by the Food and Drug Admi­nis­tra­tion (FDA) in the United Sta­tes. The ZEISS CT LUCIA 621P is an asphe­ric intrao­cu­lar lens (IOL) with a mono­fo­cal, hydro­pho­bic C‑loop design and the paten­ted ZEISS Optics (ZO) asphe­ri­city con­cept that redu­ces poten­tial decen­tra­tion pro­blems and con­fi­dently pro­vi­des good visual outcomes.

»This will become my stan­dard mono­fo­cal lens. Not only can we use it rou­ti­nely in our prac­tice, but also for more com­pli­ca­ted cases,« says Sri Ganesh, MD, chair­man and chief exe­cu­tive offi­cer of Neth­rad­hama Super Spe­cia­lity Eye Hos­pi­tal, Banga­lore, India. »Because it is a prel­oa­ded and easy-to-use lens, its use is pre­dic­ta­ble. In addi­tion, refrac­tive sta­bi­lity is relia­ble 15 days after sur­gery as well as up to three months and even up to a year after surgery.«

The ZEISS CT LUCIA 621P mono­fo­cal IOL is an important com­po­nent of the ZEISS Cata­ract Work­flow, which enables sur­ge­ons to achieve opti­mi­zed visual out­co­mes in cata­ract pati­ents. In addi­tion to the paten­ted ZEISS Optics (ZO) asphe­ri­city con­cept, the IOL also fea­tures a fully prel­oa­ded injec­tor opti­mi­zed to enable intui­tive, smooth and effi­ci­ent lens implan­ta­tion. In addi­tion, the IOL archi­tec­ture is desi­gned to allow for easy cen­tra­tion while maxi­mi­zing direct cap­su­lar cont­act. This opti­mi­zes sta­bi­lity and sup­ports a con­sis­tent posi­tion in the cap­su­lar bag.

»Even in a stan­dard case where ever­y­thing is going well, short- and/or long-term decen­tra­tion can occur because each eye has its own ana­tomy. The great thing about ZEISS optics is that they com­bine the bene­fi­cial pro­per­ties of asphe­ric and sphe­ri­cal len­ses. This makes the lens design less sus­cep­ti­ble to opti­cal decen­tra­tion, even when it is as much as one mil­li­me­ter, the opti­cal qua­lity is main­tai­ned. The ZEISS brand is syn­ony­mous with high-qua­lity optics, and that is the case here,« said Wil­liam Wiley, MD, medi­cal direc­tor, Cleve­land Eye Cli­nic (USA).

»The ZEISS CT LUCIA 621P mono­fo­cal IOL is a great exam­ple of how our latest oph­thal­mic inno­va­tions in the U.S. are dri­ving effi­ci­ency and pro­mo­ting bet­ter pati­ent out­co­mes,« said Euan S. Thom­son, M.D., head of the Oph­thal­mo­logy Stra­te­gic Busi­ness Unit and head of the Digi­tal Busi­ness Unit at ZEISS Medi­cal Tech­no­logy. »We believe this mono­fo­cal lens, as part of our ZEISS Medi­cal Eco­sys­tem and within ZEISS Cata­ract Work­flows, will improve manage­ment in sur­gery and set new stan­dards for cata­ract pati­ent care.«

The ZEISS CT LUCIA 621P mono­fo­cal IOL will be pre­sen­ted at the Ame­ri­can Society of Cata­ract and Refrac­tive Sur­gery (ASCRS) Con­fe­rence in San Diego, Cali­for­nia, May 5–8, 2023. For more infor­ma­tion, visit: https://www.zeiss.com/meditec.

Press cont­act

Sebas­tian Frericks
Direc­tor Inves­tor Relations
Carl Zeiss Medi­tec AG
Phone: +49 3641 220–116
moc.ssiez@cetidem.srotsevni

Short Pro­file

Carl Zeiss Medi­tec AG (ISIN: DE0005313704), lis­ted on the MDAX and TecDAX of the Ger­man stock exch­ange, is one of the world’s lea­ding medi­cal tech­no­logy pro­vi­ders. The com­pany deli­vers inno­va­tive tech­no­lo­gies and appli­ca­tion-ori­en­ted solu­ti­ons that enable phy­si­ci­ans to improve their pati­ents‹ qua­lity of life. For the dia­gno­sis and tre­at­ment of eye dise­a­ses, the com­pany offers com­plete solu­ti­ons, inclu­ding implants and con­su­ma­bles. In micro­sur­gery, the com­pany pro­vi­des inno­va­tive visua­liza­tion solu­ti­ons. With 4,224 employees world­wide, the group gene­ra­ted sales of 1,902.8 mil­lion euros in fis­cal year 2021/22 (Sep­tem­ber 30).

The com­pany is head­quar­te­red in Jena, Ger­many. In addi­tion to other bran­ches in Ger­many, the com­pany has more than 50 per­cent of its employees at loca­ti­ons in the USA, Japan, as well as Spain and France. The Cen­ter for Appli­ca­tion and Rese­arch India (CARIn) in Banga­lore, India, and the Carl Zeiss Inno­va­tions Cen­ter for Rese­arch and Deve­lo­p­ment in Shang­hai, China, streng­then the pre­sence in these fast-gro­wing count­ries. Appro­xi­m­ately 41 per­cent of Carl Zeiss Medi­tec shares are in free float. The remai­ning appro­xi­m­ately 59 per­cent are held by Carl Zeiss AG, a lea­ding glo­bal group of com­pa­nies in the opti­cal and opto­elec­tro­nic industry.

Fur­ther infor­ma­tion at: www.zeiss.de/med